Podcasts about therapies

Send a textWhat are we actually compressing during neonatal CPR? This week on The Incubator Podcast, Ben and Daphna dive into a provocative echocardiography study out of Edmonton showing that standard chest compressions in newborns likely target the right heart and great vessels — not the left ventricle. A small sample size, but a finding that anyone who ultrasounds hearts all day will instantly recognize.Daphna presents a retrospective multicenter study from Nationwide Children's on antibiotic duration for Gram-negative bloodstream infections in the NICU. Short course (≤8 days) showed no treatment failures — while 14% of infants in the long duration group developed a multi-drug resistant organism infection. Eight days versus ten: does the difference matter? The data says yes.Ben reviews a randomized controlled trial from UAB on early vitamin D supplementation in extremely preterm infants fed human milk. Eight hundred units daily for the first two weeks appears safe and effective at achieving vitamin D sufficiency — but did it move the needle on BPD? And is that even the right question to ask?Daphna brings a QI paper from Levine Children's on universal social determinants of health screening across nine pediatric divisions, achieving 92% compliance and connecting thousands of families to resources through findhelp.org. A reminder that the tools are already there — we just have to use them.The episode wraps with Ben, Daphna, and Eli discussing Colorado's landmark paid NICU leave law — the first in the nation to require employers to provide up to 12 weeks of paid leave for parents with a baby in the NICU. What does the evidence say, and how do we advocate for this in our own states?Science, equity, and advocacy — all in one episode.Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

This activity will discuss clinical and safety strategies for implementation that will translate to better care for patients and a safer handling environment for providers, patients, and caregivers. Additional details and discussion about collection, processing to final dose product, dose storage/preparation/administration, and safe handling may provide more insight and considerations applicable for pharmacy practice.  CE for this episode expires 2 years after the date it was originally published. The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

Osteosarcoma Webinar Series: Corey Weistuch, PhD, an Assistant Attending Physicist in the Service for Predictive Informatics within the Department of Medical Physics at Memorial Sloan Kettering Cancer Center, will discuss his OutSmarting Osteosarcoma funded work on implementing personalized, adaptive therapies in osteosarcoma.Corey Weistuch, PhD, is an Assistant Attending Physicist in the Service for Predictive Informatics within the Department of Medical Physics at Memorial Sloan Kettering Cancer Center. His work is focused on developing mathematical models to understand cancer development, progression, and metastasis by integrating multimodal data. Central to this approach is the recognition that tumors occupy a finite spectrum of functional states, each characterized by distinct treatment sensitivities and metastatic tendencies that evolve over time and in response to therapy. His research centers on two primary objectives: 1) developing innovative mathematical tools to identify cancer phenotype drivers, and 2) precision modeling of cancer evolution and site-specific metastatic dissemination. By leveraging his interdisciplinary training in mathematics and biology, he collaborates closely with experimental biologists and clinicians to ensure that his computational predictions are effectively translated into tangible clinical applications and trials.The Weistuch Lab's work aims to validate targeted drug candidates for osteosarcoma (OS) using patient-derived xenograft (PDX) models, leveraging a newly developed atlas of OS transcriptional states, called archetypes, to guide personalized, adaptive treatment strategies. By testing archetype-specific therapies in different disease phases, they establish a foundation for precision-based clinical trials, ultimately with the goal of improving outcomes for patients with advanced or refractory OS.

Send a textBen and Daphna conclude Journal Club with a quality improvement study from Pediatrics titled "Improving Health-Related Social Needs Screening and Support Across a Pediatric Health Care System". The hosts discuss the successful implementation of universal social determinants of health (SDOH) screening across nine pediatric divisions at Levine Children's. They highlight the impressive results—screening compliance reaching 92%—and the practical impact of connecting families to resources like FindHelp.org, which led to a 56% resolution rate in food insecurity for positive screens. Daphna makes a personal commitment to improve resource accessibility in her own unit.----Improving Health-Related Social Needs Screening and Support Across a Pediatric Health Care System. Laroia R, Minor W, Carr A, Buitrago Mogollon T, White BB, Mabus S, Stilwell L, Ahmed A, Mehta S, Obita T, Reed S, Senturias Y, Mittal S, Horstmann S, Demmer L, Dantuluri K, Chadha A, Noonan L, Courtlandt C.Pediatrics. 2026 Feb 5:e2024070035. doi: 10.1542/peds.2024-070035. Online ahead of print.PMID: 41638605Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

Drs. Cytryn, Foote, and Thummalapalli discuss recent data on HER2 testing modalities and the prevalence of HER2 positivity across hepatobiliary, upper GI, and colorectal cancers, highlighting implications for precision medicine. The conversation reviews the latest clinical trial findings and the evolving landscape of HER2-targeted therapies, with insights into optimal treatment sequencing for various GI cancer subtypes.

Send a textBen and Daphna review a randomized controlled trial published in The Journal of Pediatrics by Dr. Ariel Salas and colleagues at UAB. The study investigates whether early high-dose vitamin D supplementation (800 IU/day starting day 1) in extremely preterm infants reduces the incidence of Bronchopulmonary Dysplasia (BPD) compared to standard care (starting day 14). The hosts discuss the physiologic rationale linking vitamin D to lung development, the use of impulse oscillometry to measure lung mechanics, and the secondary findings regarding metabolic bone disease. They explore why the "physiologic rationale" doesn't always translate to clinical significance.----Early Vitamin D Supplementation in Infants Born Extremely Preterm and Fed Human Milk: A Randomized Controlled Trial. Salas AA, Argent T, Jeffcoat S, Tucker M, Ashraf AP, Travers CP.J Pediatr. 2025 Dec;287:114754. doi: 10.1016/j.jpeds.2025.114754. Epub 2025 Jul 24.PMID: 40714046 Clinical Trial.Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

Send a textIn this episode of Journal Club, Ben and Daphna review a retrospective cohort study from Pediatrics examining antibiotic duration for uncomplicated Gram-negative bloodstream infections in the NICU. The study, a collaboration between Nationwide Children's Hospital and UT Health San Antonio, compares outcomes between short course (≤8 days) and long course (≥9 days) therapy. The hosts discuss the startling finding that while recurrence rates were similar, the long-duration group had a 14% rate of developing multi-drug resistant (MDR) infections within 90 days, compared to 0% in the short-duration group.----Duration of Antibiotic Therapy for Gram-Negative Bloodstream Infections in the Neonatal Intensive Care Unit. Djordjevich CJ, Magers J, Cantey JB, Prusakov P, Sánchez PJ.J Pediatr. 2026 Jan 17:114993. doi: 10.1016/j.jpeds.2026.114993. Online ahead of print.PMID: 41554433 Free article.Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/FBZ865. CME/NCPD/AAPA credit will be available until January 26, 2027.Sjögren's Disease and the B-Cell Frontier: What Clinicians Need to Know Now to Prepare for Future Therapies In support of improving patient care, this activity has been planned and implemented by Boston University Chobanian & Avedisian School of Medicine and PVI, PeerView Institute for Medical Education. Boston University Chobanian & Avedisian School of Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/FBZ865. CME/NCPD/AAPA credit will be available until January 26, 2027.Sjögren's Disease and the B-Cell Frontier: What Clinicians Need to Know Now to Prepare for Future Therapies In support of improving patient care, this activity has been planned and implemented by Boston University Chobanian & Avedisian School of Medicine and PVI, PeerView Institute for Medical Education. Boston University Chobanian & Avedisian School of Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/FBZ865. CME/NCPD/AAPA credit will be available until January 26, 2027.Sjögren's Disease and the B-Cell Frontier: What Clinicians Need to Know Now to Prepare for Future Therapies In support of improving patient care, this activity has been planned and implemented by Boston University Chobanian & Avedisian School of Medicine and PVI, PeerView Institute for Medical Education. Boston University Chobanian & Avedisian School of Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/FBZ865. CME/NCPD/AAPA credit will be available until January 26, 2027.Sjögren's Disease and the B-Cell Frontier: What Clinicians Need to Know Now to Prepare for Future Therapies In support of improving patient care, this activity has been planned and implemented by Boston University Chobanian & Avedisian School of Medicine and PVI, PeerView Institute for Medical Education. Boston University Chobanian & Avedisian School of Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/FBZ865. CME/NCPD/AAPA credit will be available until January 26, 2027.Sjögren's Disease and the B-Cell Frontier: What Clinicians Need to Know Now to Prepare for Future Therapies In support of improving patient care, this activity has been planned and implemented by Boston University Chobanian & Avedisian School of Medicine and PVI, PeerView Institute for Medical Education. Boston University Chobanian & Avedisian School of Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/FBZ865. CME/NCPD/AAPA credit will be available until January 26, 2027.Sjögren's Disease and the B-Cell Frontier: What Clinicians Need to Know Now to Prepare for Future Therapies In support of improving patient care, this activity has been planned and implemented by Boston University Chobanian & Avedisian School of Medicine and PVI, PeerView Institute for Medical Education. Boston University Chobanian & Avedisian School of Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.Disclosure information is available at the beginning of the video presentation.

Dr. Tony Wyss-Coray, PhD, is a professor of neurology at Stanford School of Medicine who is discovering factors present in young blood and in exercised blood that can improve brain, heart and other organ health. We discuss how different organs age at different rates and how to accurately measure biological aging. We also discuss the specific proteins found in blood when we are young and that are increased by things such as exercise, sunlight exposure, short-term fasting, specific foods and social connection that can significantly increase vitality, restore youthful functioning of the brain and body and potentially increase lifespan. Read the episode show notes at hubermanlab.com. Thank you to our sponsors AG1: https://drinkag1.com/huberman David: https://davidprotein.com/huberman LMNT: https://drinklmnt.com/huberman ROKA: https://roka.com/huberman Function: https://functionhealth.com/huberman Timestamps (00:00:00) Tony Wyss-Coray (00:03:00) Young vs Old Animals, Age-Related Disease (00:06:35) Blood Biomarkers, Young vs Old Humans, Alzheimer's Disease (00:12:50) Sponsors: David & LMNT (00:15:28) 'Young Blood' Factors, Rejuvenation, Stem Cells (00:20:15) Blood Banking; Dracula (00:23:10) Rates of Aging in Organs, Age Gap & Disease Risk; Risk Profiles & Therapies (00:33:02) NAD Levels & Aging, NMN Supplements (00:36:44) Vitality vs Longevity; Periods of Accelerated Aging (00:43:17) Sponsors: AG1 & Roka (00:45:22) Sunlight; Youthful Blood Factors, Exercise & Brain Function, Fasting (00:51:25) Exercise, Injury & Inflammation (00:56:18) Pro-health Factors, Klotho, GDF11, Stem Cell Injection Risk (01:02:35) Platelet-Rich Plasma (PRP); Exosomes (01:05:43) Smoking, EMFs, Plastics, Long-Term Accumulation, Fresh Foods, Organic Food (01:11:28) Sponsor: Function (01:13:16) Intermittent Fasting, Long-Term Fasting, Snacking (01:19:07) Sleep; Cerebrospinal Fluid (CSF) Factors & Cognitive Function (01:24:44) Exercise Type & Longevity; Exercise Enjoyment (01:32:02) Lifestyle Factors & Alzheimer's Risk; Cognitive Exercise; Chocolate (01:37:05) Alcohol & Social Connection; US vs European Food Culture (01:40:50) Deliberate Deep Breathing; Wearables, Sunlight & Artificial Light (01:49:13) Future Projects (01:56:40) Zero-Cost Support, YouTube, Spotify & Apple Follow, Reviews & Feedback, Sponsors, Protocols Book, Social Media, Neural Network Newsletter Disclaimer & Disclosures Learn more about your ad choices. Visit megaphone.fm/adchoices

In today's episode, I welcome my friend Marcella Cox back to the podcast. Marcella is a certified IFS therapist, approved consultant, and somatic IFS assistant trainer. She's also a certified Safe and Sound Protocol (SSP) and Rest and Restore provider, and the lead author of the new guidelines for integrating IFS with these listening therapies. We talk about: The basics of polyvagal theory How our nervous system states impact our parts Why co-regulation is central to healing The difference between SSP (connection to others) and Rest and Restore (connection to Self) How listening therapies can support safety in the body and allow more Self Energy to emerge I also share my own experience trying SSP with Marcella. I experienced some surprising physical shifts and insights that came up after a few short listening sessions. If you're curious about nervous system regulation and how it can deepen your IFS work, I think you'll really appreciate this conversation. About Marcella Cox Marcella Cox, LMFT, is a therapist, author, and presenter devoted to exploring the intersection of embodiment, trauma healing, and eating disorder recovery. She is a Level 3 Certified IFS Therapist, an Approved IFS Clinical Consultant, and an Assistant Trainer for Somatic IFS, the model developed by Susan McConnell. She provides consultation and leads workshops, trainings, and retreats for professionals on IFS for disordered eating, Somatic IFS, and integrating IFS with the Safe & Sound Protocol and is the lead author of the IFS and Listening Therapies (Safe and Sound Protocol and Rest and Restore Protocol) Combined Delivery Guidelines, published through Unyte in January 2026. Marcella is the founder and executive director of Kindful Body, which provides online therapy and nutrition counseling for eating and body concerns in California. She is also the co-founder of the IFS Consultation Collective, offering weekly consultation with IFS lead trainers.  To learn more about combining IFS and Unyte's listening therapies: https://integratedlistening.com/resources/ifs-and-listening-therapies/ Marcella's SSP & IFS groups: https://www.kindfulbody.com/somatic-ifs-and-ssp-group/ Sign up for Marcella's newsletter to find out about upcoming offerings Kindful Body on Instagram - https://www.instagram.com/kindfulbody/ Episode Sponsor This episode is sponsored by Therapy Training Boston. Therapy Training Boston offers live, in-person, and online workshops, plus consultation for therapists and other helping professionals, designed to support you as a whole person while satisfying your CE requirements. All of their offerings are taught with an eye toward context, power, and relational justice, and draw on the family systems theories and best practices that shaped the IFS model. They also offer an Intensive Certificate Program in Couples and Family Therapy to help you build confidence and capacity in community.  About The One Inside I started this podcast to help spread IFS out into the world and make the model more accessible to everyone. Seven years later, that's still at the heart of all we do.  Join The One Inside Substack community for bonus conversations, extended interviews, meditations, and more. Find Self-Led merch at The One Inside store. Listen to episodes and watch clips on YouTube. Follow me on Instagram @ifstammy or on Facebook at The One Inside with Tammy Sollenberger. I co-create The One Inside with Jeff Schrum, a Level 2 IFS practitioner and coach. Resources New to IFS? My book, The One Inside: Thirty Days to Your Authentic Self, is a great place to start. Want a free meditation? Sign up for my email list and get "Get to Know a Should Part" right away. Sponsorship Want to sponsor an episode of The One Inside? Email Tammy. 

Send a textIn this episode of Journal Club, Ben and Daphna review a thought-provoking study from the Archives of Disease in Childhood titled "Chest Compression in Newborn Infants: What Anatomical Structures Are We Compressing?". The hosts explore the anatomical findings suggesting that current neonatal CPR guidelines—recommending compressions over the lower third of the sternum—may actually be targeting the right ventricle and great veins rather than the left ventricle. They discuss the implications for the "cardiac pump" vs. "thoracic pump" theories and what this means for the future of resuscitation guidelines.----Chest compression in newborn infants: what anatomical structures are we compressing? Chua CT, O'Reilly M, Surak A, Schmölzer GM.Arch Dis Child Fetal Neonatal Ed. 2026 Jan 16:fetalneonatal-2025-329582. doi: 10.1136/archdischild-2025-329582. Online ahead of print.PMID: 41545184Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

Gregory Zuckerman profiles Moderna CEO Stephane Bancel and the pivotal mRNA research by Kariko and Weissman, noting the company's difficult transition from drug therapies to vaccines. 2

Send a textDr. Sheri Fink, Pulitzer Prize-winning correspondent for The New York Times and author of Five Days at Memorial, joins us for a compelling discussion on the ethics of survival. Dr. Fink, an MD-PhD, discusses her recent article "Noah is Still Here," which chronicles one family's journey with Trisomy 18—a condition once universally deemed incompatible with life. She and Eli explore the shifting paradigms of care, the tension between medical prognosis and parental hope, and the "two truths" clinicians must hold when counseling families in the grey zone. A must-listen for anyone navigating complex bioethics in the NICU. Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

Please visit answersincme.com/860/160204316-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Tina Bhutani, MD, MAS, FAAD; and Robin K. Dore, MD. In this activity, experts in dermatology and rheumatology discuss the use of TYK2 inhibitors in the treatment of patients with psoriatic disease, including PsA. Upon completion of this activity, participants should be better able to: Discuss the rationale for using novel TYK2 inhibitors in the treatment of patients with psoriatic disease, including PsA; Review the latest evidence on the use of novel TYK2 inhibitors in patients with psoriatic disease, including PsA; and Outline multidisciplinary strategies for the optimal integration of novel TYK2 inhibitors into treatment plans for patients with psoriatic disease, including PsA.

Please visit answersincme.com/860/160204316-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Tina Bhutani, MD, MAS, FAAD; and Robin K. Dore, MD. In this activity, experts in dermatology and rheumatology discuss the use of TYK2 inhibitors in the treatment of patients with psoriatic disease, including PsA. Upon completion of this activity, participants should be better able to: Discuss the rationale for using novel TYK2 inhibitors in the treatment of patients with psoriatic disease, including PsA; Review the latest evidence on the use of novel TYK2 inhibitors in patients with psoriatic disease, including PsA; and Outline multidisciplinary strategies for the optimal integration of novel TYK2 inhibitors into treatment plans for patients with psoriatic disease, including PsA.

Please visit answersincme.com/860/160204316-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Tina Bhutani, MD, MAS, FAAD; and Robin K. Dore, MD. In this activity, experts in dermatology and rheumatology discuss the use of TYK2 inhibitors in the treatment of patients with psoriatic disease, including PsA. Upon completion of this activity, participants should be better able to: Discuss the rationale for using novel TYK2 inhibitors in the treatment of patients with psoriatic disease, including PsA; Review the latest evidence on the use of novel TYK2 inhibitors in patients with psoriatic disease, including PsA; and Outline multidisciplinary strategies for the optimal integration of novel TYK2 inhibitors into treatment plans for patients with psoriatic disease, including PsA.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of breakthroughs and strategic maneuvers that are reshaping the landscape of this dynamic industry.Roche is making waves with its antibody Gazyva, initially recognized for cancer treatment. The company has successfully ventured into autoimmune diseases, targeting kidney conditions. Recent phase 3 trials have reinforced Gazyva's efficacy in treating immune-mediated kidney diseases, building on its prior approval for lupus nephritis. This marks a potential paradigm shift from oncology to autoimmune therapy applications, offering a promising new avenue for treating complex kidney disorders. Such advancements underscore the power of immune modulation in addressing severe health conditions.Turning to oncology, Eli Lilly is expanding the use of its cancer drug, Retevmo. Originally approved for specific lung and thyroid cancers with rare biomarkers, Lilly is now exploring its use in the adjuvant setting for non-small cell lung cancer. This effort reflects a broader trend in oncology: companies are increasingly looking to extend the application of targeted therapies beyond their initial indications. This expansion could significantly enhance treatment options and improve patient outcomes.In ophthalmology, Ocular Therapeutix is preparing for an FDA filing following positive phase 3 results for its wet age-related macular degeneration treatment. Their candidate, AXPAXLI, showed superior efficacy compared to Regeneron's Eylea in head-to-head trials. Despite investor skepticism, Ocular remains confident in its product's potential to impact retinal disease management positively. The competitive landscape in ophthalmology is fierce, and innovative treatments with substantial clinical benefits over existing therapies can redefine standards of care.Eli Lilly is also strategically stockpiling Orforglipron, its oral GLP-1 candidate, in anticipation of FDA approval for obesity treatment. This proactive measure aims to prevent supply chain issues seen during previous GLP-1 launches. It reflects an industry-wide focus on ensuring product availability at launch to meet growing market demand effectively.On the regulatory front, there are significant shifts as well. The Trump administration's renewed pilot of 340B rebates aims to optimize drug pricing frameworks. Novartis has secured a long-term supply agreement with Niowave for Actinium-225 (Ac-225), crucial for developing targeted cancer therapies. This highlights the sustained demand for radiopharmaceutical isotopes as part of precision medicine initiatives.Biopharma funding is expected to recover steadily by 2026, albeit with a cautious approach favoring de-risked assets over broader platform technologies. Venture capitalists prefer predictable returns amidst an evolving market landscape.Now, let's turn to Japan, where Innovacell is planning a $92 million IPO on the Tokyo Stock Exchange. This move signals a renewed interest in biotech within the region after a long drought in IPOs. Financial strategies like these are vital for advancing cell therapies that hold promise for treating conditions once deemed challenging.Gilead Sciences has acquired synthetic lethal therapy from Genhouse Bio through a $1.5 billion deal, further underscoring the growing interest in synthetic lethality as a novel cancer treatment approach. This strategy focuses on targeting tumors while sparing normal cells, offering more effective therapies with fewer side effects.In mental health innovations, Compass Pathways has reported positive results from its pivotal trial using psilocybin for treatment-resistant depression. The success of this phase 3 trial highlights the potential role of psychedelics in psychiatric care and could revolutionize mental health treatments by providing new options Support the show

Send a textIn this premiere episode of On with Von, The Incubator launches an exciting new collaboration with the Vermont Oxford Network (VON). Hosts Dr. Ben Courchia and Dr. Daphna Yasova Barbeau sit down with Dr. Roger Soll, President of VON, and Dr. Bob White, a pioneer in NICU design, to explore the critical "Evidence to Practice" gap in the NICU environment. Moving beyond simple neuroprotection, the conversation dives into neuropromotion, examining the impact of light, sound, and sensory inputs on the developing brain. From debunking misconceptions about retinopathy to optimizing design for family integration, this discussion offers actionable insights for every bedside clinician.Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

Send a textHow much oxygen is enough when resuscitating extremely preterm infants? This week on The Incubator Podcast, Ben and Daphna explore the TORPIDO 30/60 trial comparing 60% versus 30% FiO2 at birth. While primary outcomes were similar, babies in the 60% group needed fewer chest compressions and less epinephrine—a signal worth discussing.They examine an Indian non-inferiority study on surfactant thresholds (40% vs 30% FiO2), where waiting until 40% meant significantly fewer intubations and shorter respiratory support for the youngest babies. Ben presents compelling Melbourne data showing growth-restricted preterm infants face six-fold higher NEC risk—even with identical feeding protocols—and discusses how critical birth history gets "lost" as babies grow.Daphna tackles therapeutic hypothermia in late preterm infants, reviewing Toronto's retrospective analysis showing 34-35 weekers experience higher mortality and more brain injury compared to 36-37 weekers. As units rewrite cooling protocols, are we moving too fast on limited evidence?The episode concludes with Ben, Daphna, and Eli discussing the repeal of "sensitive locations" protections for immigration enforcement. Through the story of a mother detained while visiting her NICU baby in Chicago, they explore how these policies impact family-centered care and highlight advocacy opportunities through the Protecting Sensitive Locations Act.Current research meets real-world NICU challenges—all in one episode.Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

This episode will cover the background of cellular-based gene therapies from basic cell biology to genetic targets currently used in treatment. Experts will review the mechanisms for modifying cellular genetic material and the common viral vector platforms used in ex-vivo cellular therapy production. An overview of the steps and processes for cellular therapy preparation, manufacturing, handling and administration will be provided. Additionally, this presentation will discuss novel cellular therapy agents currently approved for use and the highly anticipated cellular therapies currently under investigation. CE for this episode expires 2 years after the date it was originally published. The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

Send a textIn this episode of Neo News, the team examines the intersection of immigration policy and neonatal care. We review a recent op-ed discussing the "chilling effect" of immigration enforcement on families seeking care in "sensitive locations" like hospitals. The discussion highlights a harrowing report from The 19th about a family detained by ICE while en route to the NICU, sparking a conversation on how fear impacts parental presence and follow-up adherence. The hosts explore the Protecting Sensitive Locations Act and the critical role neonatologists play in advocating for safe access to healthcare for all families.----Vernon, L., Swenson, S., & Miller, E. (2025, October). Immigration policies are creating impossible choices for NICU families. Cleveland.com.  https://www.cleveland.com/opinion/2025/10/immigration-policies-are-creating-impossible-choices-for-nicu-families-lelis-vernon-sarah-swenson-and-emily-miller.htmlBarclay, M. L. (2025, December). Postpartum immigrant detention by ICE. The 19th. https://19thnews.org/2025/12/postpartum-immigrant-detention-ice/Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

Send a textIn this segment, Ben and Daphna review a retrospective study from the Hospital for Sick Children comparing outcomes of therapeutic hypothermia in late preterm (34-35 weeks) versus early term (36-37 weeks) infants. They discuss the significantly higher rates of mortality, hemodynamic instability, and hypoglycemia found in the younger cohort, known as "Group 1". The hosts explore the implications of using MRI scoring systems like the Weeke score for preterm brains and debate the ethical challenges of conducting future randomized trials as clinical practice shifts away from cooling younger babies based on emerging retrospective data.----Whole-body hypothermia in late preterm and early term infants: a retrospective analysis from a neurocritical care unit. Martinez A, Cikman G, Al Kalaf H, Wilson D, Banh B, Abdelmageed W, Beamonte Arango I, Christensen R, Branson HM, Cizmeci MN.Pediatr Res. 2026 Jan 7. doi: 10.1038/s41390-025-04701-x. Online ahead of print.PMID: 41501407Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

We love to hear from our listeners. Send us a message.In episode 122 of Cell & Gene: The Podcast, Host Erin Harris talks to Paul Romness, CEO of OS Therapies, to learn the company's mission to address the severe unmet need in pulmonary metastatic osteosarcoma (PMO), a rare pediatric cancer with no established standard of care once it metastasizes. Romness explains how OS Therapies' off-the-shelf HER2-targeted immunotherapy aims to significantly improve outcomes by stimulating a robust immune response with minimal side effects. He highlights results from a multicenter Phase 2B trial showing markedly improved overall survival rates compared to historical outcomes, details the company's constructive regulatory interactions with the FDA, and underscores the value of comparative canine biomarkers in development.Subscribe to the podcast!Apple | Spotify | YouTube Visit my website: Cell & Gene Connect with me on LinkedIn

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/DBK865. CME/NCPD/CPE/AAPA/IPCE credit will be available until February 8, 2027.Paving the Path for Optimal Prostate Cancer Care: Preparing Advanced Practice Providers to Integrate Modern Therapies Into Tailored Treatment Plans In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Astellas and Pfizer, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/DBK865. CME/NCPD/CPE/AAPA/IPCE credit will be available until February 8, 2027.Paving the Path for Optimal Prostate Cancer Care: Preparing Advanced Practice Providers to Integrate Modern Therapies Into Tailored Treatment Plans In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Astellas and Pfizer, Inc.Disclosure information is available at the beginning of the video presentation.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of transformative events shaping the landscape of drug development, regulatory scrutiny, and corporate strategies.At the forefront is Madrigal Pharmaceuticals' strategic acquisition of Ribo Therapeutics' preclinical siRNA programs, valued at $4.4 billion. This move aims to fortify Madrigal's liver disease drug portfolio alongside its promising candidate, resmetirom. By expanding into RNA-based therapies, Madrigal highlights an industry trend focused on gene silencing techniques to target genetic diseases more precisely.Turning to Moderna, it faces a regulatory hurdle as the FDA issued a refusal-to-file letter for its mRNA-based flu vaccine. The regulator's concerns about the trial design, specifically the use of a licensed standard-dose seasonal influenza vaccine as a control arm, emphasize the complexities of advancing mRNA technologies beyond COVID-19 applications. This situation underscores the necessity for meticulous trial designs that align with evolving regulatory standards.In cell therapy, allogeneic CAR-T treatments are gaining attention as companies strive to make these therapies more accessible by using T cells from healthy donors, rather than modifying a patient's cells. Despite technical challenges like graft-versus-host disease and immune rejection, these treatments promise streamlined manufacturing and reduced costs, marking a significant evolution from the pioneering autologous CAR-T success with Emily Whitehead in 2012. Eli Lilly's entry into CAR T-cell therapy through a $2.4 billion acquisition of Orna represents an ambitious expansion into autoimmune therapies. This strategic move exemplifies a broader trend where companies diversify portfolios to include emerging therapeutic modalities promising transformative impacts on patient care.In respiratory medicine, Upstream Bio's phase 2 trial of its TSLP receptor agonist showed encouraging results in reducing asthma exacerbations, comparable to Tezspire. However, falling short of best-case scenarios leaves room for competitors to present more compelling data. This illustrates the competitive nature of asthma treatment development and the ongoing quest for superior therapeutic options.A critical regulatory update arises from the NIH's decision to halt the Xarelto arm of a stroke prevention trial due to safety concerns. This decision highlights the indispensable role of independent monitoring committees in ensuring patient safety and meaningful clinical trial outcomes.On the corporate front, AstraZeneca has articulated an ambitious goal to achieve over 25 blockbuster drugs by 2030 as part of its strategy to reach $80 billion in revenue. This vision underscores the importance of innovation and strategic planning in sustaining growth within an increasingly competitive market.Fujifilm Biotechnologies' completion of its £400 million expansion project in the UK is another notable development, signaling robust investment in antibody production capabilities. This expansion positions Fujifilm as a key player in biopharmaceutical contract manufacturing and underscores the growing demand for flexible production technologies.The biotech sector is also witnessing significant activity with Pelage making strides in addressing hair loss through promising candidate developments. The market's enthusiasm for innovative solutions beyond traditional treatments reflects a broader demand for cutting-edge approaches to longstanding medical challenges.In obesity treatment, Novo Nordisk and Eli Lilly continue to lead with notable advancements. Novo Nordisk's recent developments with its Wegovy pill have been positively received, yet analysts question if this will suffice in maintaining their competitive edge given the dynamic nature of this therapeutic areSupport the show

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/DBK865. CME/NCPD/CPE/AAPA/IPCE credit will be available until February 8, 2027.Paving the Path for Optimal Prostate Cancer Care: Preparing Advanced Practice Providers to Integrate Modern Therapies Into Tailored Treatment Plans In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Astellas and Pfizer, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/DBK865. CME/NCPD/CPE/AAPA/IPCE credit will be available until February 8, 2027.Paving the Path for Optimal Prostate Cancer Care: Preparing Advanced Practice Providers to Integrate Modern Therapies Into Tailored Treatment Plans In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Astellas and Pfizer, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/DBK865. CME/NCPD/CPE/AAPA/IPCE credit will be available until February 8, 2027.Paving the Path for Optimal Prostate Cancer Care: Preparing Advanced Practice Providers to Integrate Modern Therapies Into Tailored Treatment Plans In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Astellas and Pfizer, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/DBK865. CME/NCPD/CPE/AAPA/IPCE credit will be available until February 8, 2027.Paving the Path for Optimal Prostate Cancer Care: Preparing Advanced Practice Providers to Integrate Modern Therapies Into Tailored Treatment Plans In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Astellas and Pfizer, Inc.Disclosure information is available at the beginning of the video presentation.

Send a textIn this episode of Journal Club, Ben and Daphna review a prospective cohort study from the Journal of Perinatology that examines the care of neonates following in-utero growth restriction. The hosts unpack the critical distinction between Fetal Growth Restriction (FGR) and Small for Gestational Age (SGA), highlighting how the "decay of information" in the NICU can lead clinicians to overlook early risk factors as babies grow. They discuss the study's alarming findings regarding the six-fold increased risk of Necrotizing Enterocolitis (NEC) in SGA infants and the importance of maintaining a comprehensive medical history throughout a patient's stay.----Care of neonates following in-utero growth restriction: A prospective cohort study exploring neonatal morbidity. Alda MG, Wood AG, MacDonald T, Charlton JK.J Perinatol. 2025 Sep;45(9):1219-1225. doi: 10.1038/s41372-025-02397-9. Epub 2025 Aug 21.PMID: 40841433 Free PMC article.Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

Dr. Joelle, a doctor of nursing practice, has created an incredible program called the Empower Method,™ in which she combines functional medicine, lifestyle, medical hypnosis, energy healing techniques and emotional release to help people heal in body, mind and spirit. Dr. Joelle overcame her own struggle with weight issues and went on to learn through experience and education that healing often requires more than the use of traditional medicine. In this episode you'll learn some of the other techniques she uses that you can use to help yourself on your adventure to becoming your best, healthiest self!The Weight Loss Winformation Podcast gives you essential psychological information to help you lose weight and more importantly, to help keep you at a healthy weight for your body! No matter how you are working to lose weight and no matter how much weight you want to lose, Weight Loss Winformation will keep you moving in a positive direction. Let's get started because well… Why Weight? (get it? Pun intended… )?Resources:·      BariAfterare: www.bariaftercare.com·      Connie Stapleton PhD website: www.conniestapletonphd.com·      BariAftercare website: https://www.conniestapletonphd.com/bariaftercare·      BariAftercare Facebook page (for members only): https://www.facebook.com/groups/BariAftercare·      Kevin Stephens: Your Bariatric Buddy   https://www.facebook.com/groups/yourbariatricbuddy/people·      Instagram: @ (Caleshia Haynes)·      Instagram: @therealbariboss (Tabitha Johnson)·      Instagram @drsusanmitchell (Dr. Susan Mitchell)·      Instagram: @lauraleepreston (Laura Preston)·      ProCare Vitamins (10% off with code ConnieStapleton)·      Rob DiMedio: https://www.busybariatrics.com/·      Dr. Joan Brugman: drjbrugman@outlook.com·      Dr. Joelle Chateauneuf https://empowerhealthandwellness.org/meet-joelle/

Send a textIn this episode of Journal Club, Ben and Daphna review a non-inferiority trial from the European Journal of Pediatrics exploring surfactant administration thresholds in preterm neonates. The study, conducted in India, compares a 30% versus 40% FiO2 threshold for babies 26-32 weeks gestational age. The hosts break down the counterintuitive findings regarding respiratory support duration in younger subgroups and discuss the broader implications of using rigid FiO2 heuristics versus individualized patient assessment. They also debate how resource availability influences clinical protocols and the potential benefits of "LISA" (Less Invasive Surfactant Administration) for avoiding intubation.----Higher (40%) versus lower (30%) FiO2 threshold for surfactant administration in preterm neonates between 26 and 32 weeks of gestational age: a non-inferiority randomized controlled trial. Haq MI, Datta V, Bandyopadhyay T, Nangia S, Anand P, Murukesan VM.Eur J Pediatr. 2025 Nov 25;184(12):793. doi: 10.1007/s00431-025-06628-1.PMID: 41288797 Clinical Trial.Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

In today's episode, our discussion features Aditya Bardia, MD, MPH, FASCO. Dr Bardia is a professor in the Department of Medicine in the Division of Hematology/Oncology, the director of Translational Research Integration, and a member of Signal Transduction and Therapeutics at the UCLA Health Jonsson Comprehensive Cancer Center in Los Angeles, California.In our exclusive interview, Dr Bardia discussed key findings from the phase 3 lidERA Breast Cancer study (NCT04961996) showing the invasive disease–free survival superiority of giredestrant (GDC-9545) over standard endocrine therapy in patients with estrogen receptor–positive, HER2-negative early breast cancer. Our discussion also covered the ongoing phase 3 INAVO123 trial (NCT06790693), which is investigating inavolisib (Itovebi) plus CDK4/6 inhibitors and letrozole in patients with endocrine-sensitive, PIK3CA-mutated breast cancer. Dr Bardia also emphasized the importance of testing for ESR1 and PIK3CA mutations in order to better personalize treatment.

Forget what you know about jail-based health care. NYC Health + Hospitals' Creative Arts Therapy program on Rikers Island is rewriting the rules on how healing happens for people in the City's custody. In this episode of The Remedy, Dr. Michael Shen sits down with Dr. Barbara Bethea, Director of Correctional Health Services Creative Arts Therapy, and music therapist Jeff Angell to explore how poetry, music, dance, and drama are providing individuals with new language for hope, self-discovery, and healing.Learn how licensed Creative Arts therapists use intentional, trauma-informed arts interventions to spark connection for individuals with serious mental illnesses and histories of substance use. Listen in on a music therapy session, hear inspiring patient stories, and discover the program's impact, from the dayroom at Rikers Island to the stage at Carnegie Hall.Is creative arts therapy the key to long-term healing? Don't miss this episode's honest insights, poetry and music from patients at Rikers Island, and groundbreaking approaches to jail-based care.Tune in now.Follow UsTwitter @NYCHealthSystemFacebook @NYCHealthSystemInstagram @NYCHealthSystemLinkedIn @NYC Health + Hospitals YouTube @NYCHealthSystem Presented by NYC Health + Hospitalswww.NYCHealthAndHospitals.org Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, we're speaking with Cindy Perettie, Executive Vice President and Global Head at Kite Pharma, a Gilead-owned company focused on curing cancer with cell therapies. Perettie talks about scaling cell therapies in the community setting, global manufacturing strategy, preparing for the launch of late-stage development programs in lymphoma and multiple myeloma, and working with partners like Arcellx. She also discusses cell therapy funding cycles and big pharma, the autologous versus allogeneic divide, why in vivo CAR-T therapies could be a game changer, what the FDA's focus on cell and gene therapies could mean for U.S. competition, and more. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

As the number of patients and survivors of cancer grows each year, awareness of the disease's emotional toll—including depression, anxiety, and deep existential distress—is increasingly recognized as a critical aspect of cancer care. In response, psychedelic-assisted therapy is gaining attention as a promising alternative to traditional mental health interventions, providing relief for some patients. To shed light on the patient experience with this treatment, CANCER BUZZ spoke with breast cancer survivor Judy Wight; Jennifer Bires, MSW, LCSW, OSW-C, FACCC, executive director of Life with Cancer and Patient Experience at Inova Health System; and Manish Agrawal, MD, cofounder and CEO of Sunstone Therapies, about the human side of psychedelic-assisted therapy, promising existing research, and how it can shape the future of psychosocial care. "It's not that I'm a different person. It's more like I'm becoming the person I was meant to be. And all those layers of trauma and sadness...I've been able to shed a lot of that." – Judy Wight "When I started to learn about psychedelic-assisted therapy, read some of the patient accounts, and see some of the research, I said, 'I've got to learn about this. I think that this could be another tool that would be useful for people in this space where we don't have the perfect answer, and we don't have the perfect treatments.'" – Jennifer Bires, MSW, LCSW, OSW-C, FACCC "When I give talks around this, I have an iceberg. Above the iceberg I have chemotherapy, surgery, and radiation, and underneath the iceberg I have what's called psychosocial, psycho-spiritual, psychological care. And I think true cancer care is treating everything in the iceberg, not just what's above the water." – Manish Agrawal, MD   Guests: Jennifer Bires, MSW, LCSW, OSW-C, FACCC  Executive Director, Life with Cancer and Patient Experience Inova Health System Fairfax, VA   Judy Wight Breast Cancer Survivor   Manish Agrawal, MD Cofounder and CEO Sunstone Therapies REKINDLE Investigator   This podcast is sponsored by Reunion Neuroscience.   Resources: The REKINDLE Study ClinicalTrials (NCT07002034) REKINDLE Brochure Reunion Neuroscience Adjustment Disorder Associated With Medical Illness: Unmet Needs and Rationale for RE104 as a Novel Psychedelic Therapy Exploring Psychedelic-Assisted Therapy in Oncology Addressing the Psychological Burdens of Cancer on World Mental Health Day Psychosocial Care in Oncology: Advocating for Policy Changes that Improve the Culture of Care Collaborative Care: A Model for Embedding Counseling in Oncology and Palliative Care Spirituality and Cultural Humility: Core Components of Comprehensive Palliative Care Psychosocial Care in Oncology Collaborative Care: A Solution for Increasing Access to Psychosocial Care in Cancer Programs and Practices Scan to learn more about the REKINDLE study:  

Don't just listen, call in with your perspective at 303-477-5600 or text to 307-200-8222 Monday - Friday from 3 pm - 6 pm MT. HOUR 1 Hour 1 of Rush To Reason opens with a hard-hitting Health & Wellness Wednesday, guest-hosted by Dr. Scott Faulkner (https://castlerockregenerativehealth.com), alongside biohacker Jeremy Sova. This hour challenges the idea that decline is inevitable, asking a blunt question: What if fatigue, brain fog, and aging symptoms are signals—not sentences? Dr. Faulkner pulls back the curtain on credibility in modern medicine, why accountability matters, and how patient-first care has been lost in a system obsessed with protocols over people. The conversation moves from heart disease prevention to cutting-edge diagnostics, exposing why “treat after disaster” thinking may be failing patients. The hour then pivots to mitochondria—the cellular power source behind energy, cognition, and resilience. In plain English, they explain why damaged mitochondria lead to low energy and why inflammation accelerates the decline. Listeners get a preview of practical, low-cost steps to rebuild cellular power, break fitness plateaus, and reclaim mental clarity. Is aging really unavoidable—or have we been ignoring the real levers of longevity? HOUR 2 Hour 2 of Rush To Reason dives deep into preventive medicine, data-driven health, and personal accountability with Dr. Scott and biohacker Jeremy Sova. This hour challenges the medical status quo by asking a simple yet uncomfortable question: What if the biggest risks to your health aren't showing up on standard tests? The conversation spans omega-3 optimization, cholesterol particle size, hormones, bone density, and why “normal labs” can still hide serious danger. The centerpiece is AI-assisted CT angiography, revealing how soft plaque—often invisible on calcium scores—can quietly lead to catastrophic heart events. A powerful listener call brings the science to life, showing how early detection can literally save lives. Dr. Faulkner also pulls back the curtain on why modern healthcare feels rushed and impersonal, tracing it to corporate medicine, electronic records, and the loss of doctor-patient relationships. This hour isn't about fear—it's about clarity, courage, and reclaiming control. Are you managing your health—or just hoping nothing breaks? HOUR 3 Hour 3 pushes listeners to the edge of what's possible in regenerative and longevity medicine with Dr. Scott Faulkner and biohacker Jeremy Sova. The hour opens with reflection on family, faith, and time—then pivots sharply into a crash course on stem cells, separating real science from dangerous hype. What's the difference between embryonic, bone-marrow, fat-derived, and umbilical-cord stem cells—and why does sourcing and regulation matter? From there, the discussion accelerates into global breakthroughs, including reports from Japan and Germany showing dramatic progress in spinal cord injury and early Alzheimer's disease. The hour stacks next-gen therapies—stem cells, plasmapheresis (therapeutic plasma exchange), and hyperbaric oxygen therapy—and explains how they may work together to extend healthspan, reduce inflammation, and even reverse markers of aging, such as telomere shortening. The final segment tees up a major reckoning in women's health, revisiting hormone replacement therapy and decades of fear driven by flawed studies. Is medicine finally shifting from managing decline to preventing it?

Drs. Coombs and Danilov explore how to optimally sequence covalent BTK inhibitors, non‑covalent BTK inhibitors (such as pirtobrutinib), and venetoclax-based regimens for relapsed CLL, emphasizing real-world data and emerging trial results. They highlight that treatment choices hinge on prior response depth and duration, tolerability, mutational profile, and the need to preserve future options and clinical trial eligibility.

Alberto Ciccia, Professor of Genetics and Development at Columbia University, joins us to discuss how cells protect their genomes and how these pathways intersect with cancer and immunity. He explains how his lab uses CRISPR-based genome-editing tools to map the DNA damage response and uncover new therapeutic targets. We also talk about his recent Cell study showing how the DNA damage response factor SMARCAL1 shapes immune signaling and tumor immune evasion. Throughout the conversation, Professor Ciccia reflects on mentorship, scientific creativity, and how advances in DNA repair research could translate into better diagnostics and treatments for patients.Hosted by Sophia Deng.

This episode will provide opportunities for the health-system pharmacist to improve understanding of in vivo and viral-based therapies on an institutional level, outline strategies for toxicity prevention and management, and provide recommendations to ensure availability of supportive care therapies to maintain patient safety, when needed. CE for this episode expires 2 years after the date it was originally published. The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

Dr. Tesha Monteith and Dr. Michael Eller discuss the implications of CGRP therapies in migraine treatment, particularly for patients with vascular risk factors or a history of stroke.  Show citation: Eller MT, Schwarzová K, Gufler L, et al. CGRP-Targeted Migraine Therapies in Patients With Vascular Risk Factors or Stroke: A Review. Neurology. 2025;105(2):e213852. doi:10.1212/WNL.0000000000213852  Show transcript:  Dr. Tesha Monteith: Hi, this is Tesha Monteith with the Neurology Minute. I've just been speaking with Michael Eller from the Department of Neurology Medical University of Innsbruck, Austria on the neurology podcast on his paper, CGRP Targeted Migraine Therapies in Patients with Vascular Risk Factors or Stroke: A Review. Hi, Michael. Dr. Michael Eller: Hello. Dr. Tesha Monteith: Why don't you summarize your general approach to use of CGRP targeted therapies in patients that might be at risk for vascular events when considering safety? Dr. Michael Eller: Yeah. About acute vascular events, we should stop CGLP targeted drugs immediately. When we come to post-stroke, we should reassess the necessity of these targeted treatments after recovery. We suggest a minimum of three months pause after ischemic stroke to allow early recovery and remodeling, and then restart only after individualized benefit risk review. In high-risk primary prevention, so no stroke yet, but elevated risk, if the patients are 65 years or older with established cardiovascular disease, we should prefer traditional preventives. And if CGLP targeted therapy is essential, we should consider Gepants cautiously due to their shorter half lives. We should avoid CGLP targeted treatments in small vessel disease, distal stenosis, Raynaud's phenomenon, and uncontrolled hypertension. For acute migraine treatment, we can consider gepants or ditans as alternatives to triptans and NSAIDs in relevant stroke risk or post-stroke patients, individualized to comorbidities. Dr. Tesha Monteith: Great. And we should say that the label updates include hypertension and Raynaud's phenomenon as potential vascular complications. Otherwise, these are more theoretical risks based on what we know about CGRP. Dr. Michael Eller: Yes, I totally agree because large studies did not show any elevated cardiovascular risk signals. And for post-marketing databases, we did not see any elevated cardiovascular risk so far. However, in pre-clinical settings, studies showed large infarct size in pretreated mice. Dr. Tesha Monteith: Great. Well, thank you again for doing this work. It was a phenomenal read and congratulations. Dr. Michael Eller: Thank you. Dr. Tesha Monteith: This is Tesha Monteith. Thank you for listening to the Neurology Minute.

Fear-based learning can intensify pain in people with IBD even when inflammation is no longer active, showing that emotional processing plays a major role in chronic symptoms IBD patients in remission reported significantly higher pain intensity and unpleasantness compared to healthy individuals, despite experiencing the exact same heat stimulus The brain can hold onto pain memories through a process called fear conditioning, which teaches the nervous system to expect discomfort even without a current physical trigger People with IBD often feel isolated and emotionally overwhelmed due to unpredictable flare-ups, brain fog, shame, and the invisible nature of their pain Therapies like cognitive behavioral therapy offer a promising path to reduce pain by addressing the brain's learned fear responses

Dr. Tesha Monteith talks with Dr. Michael Eller about the implications of CGRP therapies in migraine treatment, particularly for patients with vascular risk factors or a history of stroke.  Read the related article in Neurology®. Disclosures can be found at Neurology.org. 

View the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter's Weekly Newsletter Lisa Mosconi is a world-renowned neuroscientist and the director of the Women's Brain Initiative at Weill Cornell Medicine, where she studies how sex differences and hormonal transitions influence brain aging and Alzheimer's disease risk. In this episode, Lisa explores why Alzheimer's disease disproportionately affects women and why longer lifespan alone does not explain their nearly twofold risk compared to men. She explains why Alzheimer's disease may be best understood as a midlife disease for women, beginning decades before symptoms appear, and how menopause represents a fundamental brain event that reshapes brain energy use, structure, and immune signaling. The conversation also examines what advanced brain imaging reveals about preclinical Alzheimer's disease, estrogen receptors in the brain, and why genetic risks such as APOE4 appear to affect women differently from men. Finally, Lisa discusses the nuanced evidence around menopause hormone therapy, the legacy of the WHI, her new CARE Initiative to cut women's Alzheimer's risk in half by 2050, and practical, evidence-based strategies to support brain health through midlife—including lifestyle, sleep, metabolism, mood, and emerging therapies such as GLP-1 agonists and SERMs (selective estrogen receptor modulators). We discuss: How Lisa's personal family history and scientific background led her to focus on the intersection of women's health, brain aging, and Alzheimer's disease (AD) [2:45]; The long preclinical phase of AD and the emotional burden carried by patients before dementia becomes severe [7:15]; How AD compares to other common forms of dementia: prevalence, pathology, symptoms, diagnostic challenges, and more [10:45]; Why AD disproportionately affects women: how AD is not simply a disease of old age or longevity but a midlife disease in which women develop pathology earlier [16:15]; Menopause as a leading explanation for women's increased Alzheimer's risk, and how advanced braining imaging can detect early changes in the brain [26:15]; How a new method for imaging estrogen receptors in the brain is changing how we think about the menopause transition [35:45]; What estrogen receptor imaging can and cannot tell us about hormone therapy's potential impact on brain health [48:45]; Lisa's studies on the relationship between levels of systemic estrogen and density of estrogen receptors in the brain [58:00]; Why blood estrogen levels poorly reflect brain estrogen signaling, and how tightly regulated brain hormone dynamics complicate our understanding of menstrual-cycle and lifestyle effects [1:02:15]; The CARE Initiative: Lisa's research program looking to slash AD rates in women [1:07:45]; The dramatic difference in AD risk between men and women associated with APOE4 [1:10:45]; What the evidence suggests about menopausal hormone therapy (MHT) and AD risk, and why timing, formulation, and uterine status appear to matter [1:12:00]; How the CARE initiative plans to study MHT and AD risk, within the practical constraints of a three-year research window [1:17:30]; How to think about starting hormone therapy during perimenopause: balancing symptom relief, hormonal variability, and individualized care [1:21:00]; Investigating selective estrogen receptor modulators (SERMs) as a targeted approach to brain health during and after menopause [1:25:00]; Why estrogen became wrongly associated with cancer risk and what the evidence actually shows [1:29:30]; Why better biomarkers are central to advancing women's Alzheimer's research [1:38:30]; Modifiable risk factors for dementia, the limitations of risk models, and questionable conclusions drawn from observational data [1:44:15]; GLP-1 agonists and brain health: exploring potential neuroprotective effects of GLP-1 agonists beyond metabolic benefits [1:49:00]; The importance of lifestyle factors in reducing risk of dementia: practical strategies for women to support brain health [1:53:45]; Why long-term, consistent lifestyle habits are essential for building cognitive resilience and protecting brain health over decades [2:01:15]; and More. Connect With Peter on Twitter, Instagram, Facebook and YouTube